Navigation Links
Novexel to be Acquired by AstraZeneca
Date:12/23/2009

rica. - NXL103, an oral Streptogramin antibiotic. NXL103 is currently in a Phase II clinical trial in adults with acute bacterial skin and skin structure infections (ABSSSI). The trial is designed to assess the safety and efficacy of NXL103 in comparison to oral linezolid. NXL103 has already delivered positive Phase II results in a trial evaluating it in the treatment of community acquired pneumonia (CAP).

In addition, Novexel has two further programmes in preclinical development: NXL105, a novel anti-Pseudomonal antibiotic and NXL201, a novel echinocandin antifungal agent.

Iain Buchanan, Novexel's CEO, said, "Today's announcement highlights the significant progress that Novexel has made since it was spun out of Aventis Pharma S.A. in December 2004 and demonstrates the added value of placing promising assets in an entrepreneurial structure in France. Over the last five years we have made the appropriate decisions to advance the pipeline and I would like to pay tribute to all Novexel employees whose collective efforts have made this transaction with AstraZeneca possible. I am confident that the acquired assets will receive continued investment from both AstraZeneca and Forest and will have the possibility to play an important therapeutic role to combat resistant organisms in the hospital."

Goldman Sachs acted as financial advisor to Novexel on this transaction.

Notes to Editors

About Novexel

Novexel is a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The ever increasing resistance to marketed antibiotics has led to a clear need for

novel drugs that are active against multi-drug resistant bacteria. Novexel's products are targeting the global hospital antibiotic market, which was worth an estimate
'/>"/>

SOURCE Novexel
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
2. Novexel to Present Five Posters at the Joint Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America (ICAAC/IDSA) Meeting
3. Novexels NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections
4. Novexels NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
5. Novexel to Present Four Posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases in Helsinki
6. Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
9. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
10. Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA
11. Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 2015 Insulet Corporation (NASDAQ: PODD ), ... OmniPod ® Insulin Management System, today announced preliminary ... 2015. The Company also announced that it will postpone ... and conference call from Thursday, July 30, as originally ... Highlights: , Preliminary second quarter ...
(Date:7/29/2015)... SANTA MONICA, Calif. , July 29, 2015 /PRNewswire/ ... to the San Diego Marriott Marquis & Marina on ... the medical device industry. A highlight of the Business ... Secure Financial Backing from Different Types of Investors, featuring ... Johnson & Johnson Development Corporation; Brent Ahrens , ...
(Date:7/29/2015)... 29, 2015  According to data released today by ... average monthly Medicare Part D premium is expected to ... was originally projected, the Pharmaceutical Care Management Association (PCMA) ... to be a bright spot in American health care. ... region and using cutting edge, cost-saving tools like pharmacy ...
Breaking Medicine Technology:Insulet Reports Preliminary Second Quarter 2015 Revenue Results 2Insulet Reports Preliminary Second Quarter 2015 Revenue Results 3Insulet Reports Preliminary Second Quarter 2015 Revenue Results 4Insulet Reports Preliminary Second Quarter 2015 Revenue Results 5MEDevice San Diego Offers Tips on Securing Financial Backing from Investors 2
(Date:7/30/2015)... ... 30, 2015 , ... New research finds some distinct differences in the way ... on the Surviving Mesothelioma website. , Researchers with the National Institutes of Health, ... cases of mesothelioma occurring between 1990 and 2010. Two percent of these cases (207) ...
(Date:7/30/2015)... Angeles, California (PRWEB) , ... July 30, 2015 , ... ... August 5th 2015 - “Learn How to Make Money in the Booming Homecare Business.” ... Los Angeles CA 90010. , The event will be hosted by ...
(Date:7/30/2015)... ... 2015 , ... After conducting a nationwide executive search led by healthcare leadership ... Far Rockaway, N.Y., has hired Gerard (Jerry) Walsh as Chief Executive Officer. Walsh assumed ... leadership experience, Walsh is an expert in organizational change, physician development, implementation of quality ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... with its Medicare administrative contractor (MAC) over submitted claims for bariatric surgery that, ... a challenge to program integrity, Becky Dennis, a nurse auditor at WellSpan Health, ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... largest amount of research grants in its history of funding brain aneurysm research. ... who have dedicated their life’s work toward scientific research directed at early detection, ...
Breaking Medicine News(10 mins):Health News:Study Finds Mesothelioma Behaves Differently in Younger People, According to Surviving Mesothelioma 2Health News:Upcoming Business Seminar at 1Heart Caregiver Services Headquarters Los Angeles California 2Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 2Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 3Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 4Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 5Health News:Hospital Details Fight for Bariatric Surgery Reimbursement in AIS Newsletter 2Health News:Hospital Details Fight for Bariatric Surgery Reimbursement in AIS Newsletter 3Health News:Brain Aneurysm Foundation to Award Largest Amount of Research Funding 2Health News:Brain Aneurysm Foundation to Award Largest Amount of Research Funding 3Health News:Brain Aneurysm Foundation to Award Largest Amount of Research Funding 4
... drugs meant for treating HIV patients also served to protect ... the same can be applied to human beings also has ... ,Rhesus monkeys were experimented upon by the ... them with a version of the Truvada, manufactured by Gilead ...
... older adults due to brain related changes, according to ... easy where younger adults are concerned. The healthy middle ... good where concentrating is concerned, according to functional magnetic ... of the Rotman Research Institute at the Baycrest Center ...
... rates of patients, specific for every surgeon in Scotland has ... community. A majority of the surgeons feel that the ... the surgeon, list of hospitals in which the surgeon has ... the associated mortality rate are amongst the details published. The ...
... that there has been an increase in heart failure cases among ... with men surviving for longer periods. There has been a ... to 1994 period when compared to the 1970 to 1974 period, ... the study. ,The chances of heart failure occurring ...
... National Institute of Immunology are reported to have identified ... the tuberculosis (TB) bacteria survives in the human body. ... more effective medicines to combat the disease, which claims ... annually. The research team led by Rajesh S. Gokhale ...
... A team of researchers led by Dr Stephen Harbarth have ... to be useful in reducing the // infection rates ... by the NHS in dealing with the bug. ... in patient swabs. The researchers said that this test was ...
Cached Medicine News:Health News:The Publication Of Surgeon Specific Death Rates Raises Controversy 2
1.5 mm x 12 mm tip. Angled 15 degrees. Teflon coated with diathermy attachment....
2 mm diameter blade. Angled 60 degrees. Sharp. Round handle....
2 mm. Angled 13 degrees, 15 mm from angle to tip. Round handle....
1.25 mm x 2.5 mm blade. 135 degrees back scratcher. Round handle....
Medicine Products: